Drug resistance and Cancer stem cells.

Li Y, Wang Z, Ajani JA, Song S. · 2021

Read Drug resistance and Cancer stem cells. by Li Y, Wang Z, Ajani JA, Song S. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7885480.txt.

Introduction

Li and co-authors present a review of drug resistance in cancer, with a focus on cancer stem cells. Tumours often learn to withstand the drugs used against them. The surviving cells can be fitter and more aggressive. The review explains the main routes to that resistance.

Some resistance is present from the start, and some is gained during treatment. The authors cover drug efflux pumps, changes that dodge cell death, and DNA damage responses. Cancer stem cells sit at the centre of their account. These self-renewing cells resist standard treatment and adapt to shifts around them. The review ends with strategies to wipe out such cells. It frames combination treatment as the most likely way past resistance.

Catalog record

CREATORLi Y, Wang Z, Ajani JA, Song S.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7885480

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Drug resistance and Cancer stem cells By Yuan Li, Zhenning Wang, Jaffer A Ajani, Shumei Song Published in: Cell Communication and Signaling : CCS DOI: 10.1186/s12964-020-00627-5 ABSTRACT Abstract Therapy resistance is a major problem when treating cancer patients as cancer cells develop mechanisms that counteract the effect of therapeutic compounds, leading to fit and more aggressive clones that contribute to poor prognosis. Therapy resistance can be both intrinsic and/or acquired. These are multifactorial events, and some are related to factors including adaptations in cancer stem cells (CSCs), epithelial-mesenchymal transition (EMT), deregulation of key signaling pathways, drug efflux through ABC transporters, acquired mutations, evading apoptosis, and activation of DNA damage response among others. Among these factors, CSCs represent the major source of therapy resistance. CSCs are a subset of tumor cells that are capable of self-renewal and multilineage progenitor expansion that are known to be intrinsically resistant to anticancer treatments. Multiple clones of CSCs pre-exist, and some can adopt and expand easily to changes in the tumor microenvironment (TME) and/or in response to radio- and chemotherapy. A combination of both intrinsic and extrinsic factors contributes to CSC-mediated therapy resistance. In this review, we will focus on CSCs and therapy resistance as well as suggest strategies to eliminate CSCs and, therefore, overcome resistance. [Figure: Video abstract.] Supplementary Information The online version contains supplementary material available at 10.1186/s12964-020-00627-5. Keywords: Drug resistance, Cancer stem cells, EMT and TME INTRODUCTION Tumors harbor heterogeneous clones of cancer stem cells (CSCs) representing the fundamental properties for survival [1]. In recent years, addressing the origin of intratumor heterogeneity (ITH) has become one of the core challenges for overcoming therapy resistance. The clonal evolution model considers tumors to be the result of random evolution, while the CSC model considers tumor heterogeneity due to the presence of CSCs [2, 3]. CSCs are defined as “cells that have the ability to self-renew and also create a progeny”. Therefore, the bulk of cancer mass is formed by the differentiated and expanded progeny with high proliferation potential while harboring small populations of various CSCs. At present, cure of tumor remains a major challenge for oncologists due to advanced stage of most cancers and the presence of resistant CSC clones [4, 5]. It has been proposed that targeting CSC subpopulations can result in tumor elimination thus no likelihood of tumor relapse [6]. CSCs evade conventional therapies by remaining dormant, have increased DNA repair capacity, turn off apoptotic pathways, manage reactive oxygen species (ROS) and reactive nitrogen species (RNS) in a highly competent manner, and by manipulating TME (tumor microenvironments) to their advantage [7]. POTENTIAL CSCS MARKERS AND THERAPY RESISTANCE In essence, CSCs are defined by their intrinsic ability to propagate the tumor, thereby explaining the alternative names “tumor initiating cells” or “tumorigenic cells” [8]. CSCs can be identified by various surface markers. To date, several CSC markers in different tumor types have been proposed and validated through cell lines, patient samples, and xenotransplantation of CSCs in animal models. Followings are the CSC biomarkers of interest: CD133, also known as prominin-1, a glycoprotein with five transmembrane domains, was identified from mouse neuro-epithelial stem cells and human hematopoietic stem cells. The expression of CD133 is not restricted to normal stem cell, but also found in many tumor types. Dirks et al. discovered that CD133 expressed in brain tumors and used CD133 as a CSC marker to identify brain CSCs [9]. CD133 was also identified in various other tumors including breast, stomach, colon, prostate, liver, pancreatic, ovarian, lung cancer, and head and neck squamous cell cancers [10–14]. CD133-expressing CSCs exhibited self-renewal potential and over-expression of CD133 has been associated with poor prognosis and reduced overall survival in gastric adenocarcinoma and several other tumor types [15]. High expression of CD133 is associated with drug resistance. The presence of CD133-positive CSCs in lung cancer increases the expression of the ABC transporter ABCG2, resulting in lung cancer resistance to first-line drugs such as platinum and paclitaxel. Studies have shown that low-dose platinum therapy can cause DNA damage rather than cell death, which can induce ABCG2 upregulation and further increase the number of CD133-positive cells. Specific ABCG2 inhibitor Pantoprazole or ABC transporter inhibitor Verapamil can reduce tumor resistance to platinum [16]. It has been reported that CD133 mediates cisplatin resistance that can overcome by inhibition of CD133 [17]. CD44, is a transmembrane receptor for hyaluronic acid (HA) and many other extra-cellular matrix (ECM) components and a coreceptor for growth factors and cytokines. It is reported that CD44 is associated with increased potential for tumor initiation and progression [18]. CD44 is an important cell surface molecule that can sense, integrate, and transduce cellular microenvironment signals to membrane-associated cytoskeleton proteins or to nuclei, thereby regulating the expression of various genes that control cell behaviors. Increasing evidence suggests that CD44, especially the CD44v subtype, is a CSC biomarker and a key regulator of cancer stemness, metastases, and response to therapy [19]. ALDH1, is a member of the aldehyde dehydrogenase (ALDH) superfamily of enzymes, which comprises 19 human isozymes. ALDH1 is known to participate in many important physiological biosynthetic pathways, and certain ALDH1 activities have been shown to be crucial in the detoxification of specific endogenous and exogenous aldehyde [20]. Many studies indicate that ALDH1 is involved in therapy resistance. ALDH1 controls the oxidation of aldehydes to corresponding acids, and ALDH-mediated detoxification of toxic aldehyde intermediates produced in cancer cells treated with certain therapeutic agents has been proposed to confer therapy resistance to ALDH1+ tumor cells [21]. In esophageal cancer, ALDH1high is associated with reduced response in chemoradiation and chemotherapy [22]. Meng’s study indicates that ALDH1 expression is also correlated to the platinum resistance in ovarian cancer by regulating cell cycle checkpoints and the DNA repair pathway [23]. Using ALDH1 sorting, Nguyen et al. found that ALDH1+ CSCs had higher tumorigenicity in mice and were more resistant to therapy than ALDH1− gastric cancer cells [24]. Study from our laboratory also demonstrated that ALDH1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients and we found that sorted ALDH1+ cells were more resistant and had an aggressive phenotype than ALDH1- cells [22]. Targeted inhibition of ALDH1 could prevent recurrence of the tumor driven by ALDH1+ CSCs [25]. Therefore, as a detoxifying enzyme, ALDH1 is highly expressed in CSCs to alleviate the toxic effects of ROS and to control the cell cycle so that the cells have enough time for DNA repair, which enables CSCs to resist therapy. CD166, also named as activated leukocyte cell adhesion molecule (ALCAM), is a glycoprotein belonging to the immunoglobulin superfamily of adhesion molecules [26]. Unlike other adhesion molecules such as E-cadherin which are usually down-regulated during malignant transformation, CD166 often shows increased expression in certain cancers [27]. Overexpression of CD166 in papillary thyroid carcinoma (PTC) was independently associated with a shorter progression-free survival, higher nodal and tumor stages suggesting that CD166 may be a potential therapeutic target to treat PTC [28]. CD166 has been implicated as CSCs marker in many cancer types such as colon, stomach and head/neck [24, 29]. Recent study from Satar NA et al. demonstrated that CD166/EpCAM/CD44 triple positive clones mediated therapy resistance and putative CSC characteristics in human non-small cell lung cancer

Read the complete text